Comparing Coeptis Therapeutics (NASDAQ:ZSQR) & Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Earnings & Valuation

This table compares Gossamer Bio and Coeptis Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$55.54 million	0.72	-$170.37 million	($0.79)	-0.21
Coeptis Therapeutics	$1.36 million	323.71	-$11.92 million	($2.52)	-3.40

Coeptis Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Profitability

This table compares Gossamer Bio and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Insider and Institutional Ownership

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Gossamer Bio and Coeptis Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2	4	4	0	2.20
Coeptis Therapeutics	1	0	0	0	1.00

Gossamer Bio currently has a consensus price target of $4.50, suggesting a potential upside of 2,551.74%. Given Gossamer Bio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Coeptis Therapeutics.

Summary

Gossamer Bio beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.